Forxiga/Farxiga meets goal of pediatric type 2 diabetes trial

4 October 2023

Positive results from the T2NOW Phase III trial have demonstrated significant reduction in A1C, a marker of average blood sugar, for patients treated with Forxiga/Farxiga (dapagliflozin) compared to those receiving placebo.

The trial is one of the largest pediatric type 2 diabetes studies performed to date.

Adjusted mean change in A1C was −0.62% for AstraZeneca’s (LSE: AZN) SGLT2 inhibitor versus +0.41% for placebo. Statistical significance was achieved on the primary endpoint and all secondary endpoints versus placebo at week 26, establishing that Forxiga can provide clinically meaningful improvements in glycemia for children and adolescents with type 2 diabetes.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK